NIH Charters Cancer Advisory Panel on Alternative Medicine

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 6
Volume 8
Issue 6

BETHESDA, Md-The National Institutes of Health (NIH) has chartered its Cancer Advisory Panel for Complementary and Alternative Medicine, limiting the group’s lifetime to 2 years unless it is formally renewed.

BETHESDA, Md—The National Institutes of Health (NIH) has chartered its Cancer Advisory Panel for Complementary and Alternative Medicine, limiting the group’s lifetime to 2 years unless it is formally renewed.

The panel was initially organized last November to advise the directors of the NIH, the National Cancer Institute, and the National Center for Complementary and Alternative Medicine. The 13-member panel assesses summaries of evidence and makes recommendations about future directions in research. It is chaired by Ernst Wynder, MD, of the American Health Foundation.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content